The cancer and autoimmune disease drug developer completed a Legend Star-backed series D round led by Mirae Asset Financial Group.

US-based biotherapy developer HifiBio Therapeutics raised $75m in series D funding yesterday from investors including Legend Star, a corporate venturing subsidiary of conglomerate Legend Holdings.

Financial services and investment group Mirae Asset Financial Group led the round, which included B Capital Group, Sherpa, Maison Capital, Trinity Innovation Fund, Grand Mount, HKSTP Venture Fund, IDG Capital, Sequoia Capital and Hengxu Capital.

Founded in 2013, HifiBio is working on antibody treatments for patients suffering from cancer or autoimmune diseases, combining biological know-how…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
Email LinkedIn